Suzhou Aifeitang Pharmaceutical Technology

Suzhou Aifeitang Pharmaceutical Technology is a Chinese biotechnology company focused on the discovery and development of innovative small molecule therapeutics for oncology. The company specializes in targeting difficult-to-drug proteins, with a primary focus on the KRAS signaling pathway, including specific mutations such as G12D and G12V. Utilizing a structure-based drug design platform, Aifeitang aims to develop high-potency inhibitors for various solid tumors, including pancreatic and colorectal cancers. The company is currently in the pre-clinical stage, advancing a pipeline of selective KRAS inhibitors toward clinical trials.